Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.01 (-2.37%)
Close on Nov 20, 2026Market cap $728.18KP/E –Yield –
Aptevo Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Aptevo Therapeutics's free cash flow for the twelve months ending Dec 31, 2022 was -$21.05M. For fiscal 2022 it was -$21.05M. The highest annual figure on record is -$21.05M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$21.05M | – |
| FY2021 | Dec 31, 2021 | -$22.39M | – |
| FY2020 | Dec 31, 2020 | -$29.41M | – |
| FY2019 | Dec 31, 2019 | -$42.54M | – |
| FY2018 | Dec 31, 2018 | -$52.40M | – |
| FY2017 | Dec 31, 2017 | -$42.98M | – |
| FY2016 | Dec 31, 2016 | -$39.37M | – |
| FY2015 | Dec 31, 2015 | -$50.29M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -$5.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.10M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.89M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.34M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.10M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.45M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.75M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.69M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.82M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.24M | – |
| Q3 FY2016 | Sep 30, 2016 | -$88.00K | – |
See a number that looks wrong?